CNSY Stock — Cerenome, Inc.

Cerenome, Inc. (CNSY)

Updated October 16, 2026.

CNSY is a Stock. Total return is -100.0% over the past 25.3 years, 1015.2 points behind SPY at 915.2%.

Cerenome, Inc. is a clinical-stage pharmaceutical company developing radiotherapeutic and diagnostic treatments for cancer patients, with lead candidates including rhenium obisbemeda for central nervous system and brain cancers and a diagnostic test to identify metastasized tumor cells. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to early-stage cancer treatment development, though it carries the risks associated with clinical-stage pharmaceutical companies that have not yet commercialized their primary products.

CNSY performance versus SPY

Price and return data through 2026-10-16.

Total return is -100.0% over the past 25.3 years, 1015.2 points behind SPY at 915.2%. Over the past year its total return — price change plus distributions reinvested — is -88.8%. Its deepest 1-year drawdown was 91.3%.

CNSY key facts

Asset type

Stock

Asset class

Equity

Inception date

07/11/2001

Distribution frequency

None

Last close

$1.70 (as of 2026-10-16)

Market cap

$12,902,362

Average volume

84939.0

Beta

1.471

Payout ratio

0.0%

Forward P/E

0.9696

EPS

$-3.63

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CNSY risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 91.3%.

Who may consider CNSY — and who may not

It is a weaker fit for investors who need monthly cash flow (CNSY does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CNSY

• All tickers starting with C

Frequently asked questions